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Abstract
Background. Opioidergic conditioning is well documented to trigger cardioprotection against ischemia/
reperfusion (I/R) injury. Previous studies on animal models have suggested that nitric oxide (NO) mediates 
the beneficial effect of opioids, but the role of NO in humans seems to be controversial.
Objectives. The aim of the study was to assess the influence of NO modulators on opioid-induced cardio-
protection in the human myocardium.
Material and methods. Trabeculae of the human right atria were electrically driven in an organ bath and sub-
jected to simulated I/R injury. The non-selective inhibitor of nitric oxide synthase (NOS) – N-methyl-l-arginine 
(LNMMA), the donor of NO – S-Nitroso-N-acetylpenicillamine (SNAP) or morphine (in the amount of 10−4 M) 
were used at the time of re-oxygenation. The additional trabecula was subjected to the hypoxia protocol only 
(control). The contractility of the myocardium was assessed as the maximal force of a contraction (Amax), 
the rate of rise of the force of a contraction (Slope L) and the cardiac muscle relaxation – as the rate of decay 
of the force of a contraction (Slope T).
Results. The application of 100 µM LNMMA resulted in the decrease of Amax, Slope L and Slope T during 
the re-oxygenation period as compared to control. The application of 10−4 M morphine and/or 100 µM SNAP 
resulted in a partial reversal of the detrimental influence of LNMMA.
Conclusions. At the re-oxygenation period, the blockade of NO synthesis has a deleterious effect on the sys-
tolic and diastolic function of the human myocardium as well as attenuates the beneficial effect of morphine 
conditioning.
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Introduction
Ischemic heart disease is known as the leading cause 
of morbidity and mortality in adults. Early reperfusion 
is necessary to restore perfusion of the ischemic heart 
muscle. However, reperfusion may induce a  cascade 
of pathophysiological reactions, increasing the infarct area 
of the myocardium by up to 50% of the final size.1 Sequenc-
es of brief episodes of non-lethal ischemia and reperfusion 
applied before (ischemic preconditioning – IPC) or after 
(ischemic postconditioning – POC) the coronary occlusion 
are well documented to reduce ischemia/reperfusion (I/R) 
injury. Regarding the fact that applying these techniques 
in humans is impractical, as well as that the results from 
human trials have been controversial,extensive research ef-
forts have been made to find pharmacological agents which 
can mimic these cardioprotective strategies.2–4 The mech-
anisms underlying IPC or POC are still not clarified, but 
strong experimental evidence suggests that opioids may be 
a part of the endogenous cardioprotective response to I/R 
injury and trigger intracellular enzyme cascades, leading 
ultimately to the closure of the mitochondrial permeabil-
ity transition pores (mPTP), responsible for the induc-
tion of cell damage.5 Previous studies on animal models 
have suggested the nitric oxide (NO)/cyclic guanosine 
monophosphate (cGMP) signaling as the main pathway 
involved in the beneficial effect of opioids, but our un-
derstanding of the role of nitric oxide synthases (NOS) 
in  modulating I/R injury in  humans remains limited. 
We hypothesize that the opioid receptor activation pro-
vides cardioprotection in the human heart muscle through 
a NO-dependent pathway, which may give insight into 
explaining the protective mechanisms against I/R injury.
Material and methods
Material
The  experiments were performed on  muscular tra-
beculae obtained from the right heart atrial appendages 
of 58 consecutive patients (35 males and 23 females) sub-
jected to the coronary artery bypass surgery. Patients diag-
nosed with significant valvular heart disease or with severe 
heart failure were excluded from the study. The patients’ 
demographic data is presented in Table 1.
Methods
Fragments of the human right heart atria were transported 
from the cardiac surgery room to the laboratory in the ice-
cold Krebs-Henseleit solution ([M]: 118.0 NaCl, 4.70 KCl, 
1.52 CaCl2, 1.64 MgSO4, 24.88 NaHCO3, 1.18 KH2PO4, 
11.0 glucose, and 2.0 sodium pyruvate; pH 7.4). Two mus-
cular trabeculae were dissected from the right heart atria 
and incubated in 2 separate organ baths (Schuler Organ 
Bath, Hugo Sachs Elektronik – HSE, March-Hugstetten, 
Germany), both filled with the Krebs-Henseleit solution 
warmed up to 37°C. To avoid core hypoxia, the trabeculae 
included in the study had a cross-sectional area <1 mm 
in diameter. Two trabeculae from each patient were al-
ways studied simultaneously and exposed to  the  hy-
poxia protocol including 60  min of  hypoxia (incuba-
tion in the Krebs-Henseleit buffer deprivated of glucose 
and pyruvate saturated with 95% argon and 5% carbon 
dioxide) with subsequent 60 min of re-oxygenation (in-
cubation in  the Krebs-Henseleit buffer saturated with 
the  95% oxygen and 5% carbon dioxide). The  buffer 
was replaced every 15 min, except the time of hypoxia. 
Every trabecula was stretched to 90% of its optimal tension 
strength according to the Frank-Starling relationship, and 
all trabeculae were driven throughout the experiments with 
1 Hz 50 ms square stimuli, using platinum field electrodes 
and a stimulator (Type 215, HSE). The contractive function 
of every trabecula was recorded with the use of a transduc-
er (Type 372, HSE). The signal was enhanced with a bridge 
amplifier (Type 336, HSE), and recorded by a PowerLab/4SP 
system and analyzed off-line using Chart software (ADIn-
struments, Chalgrove, UK). Each experimental protocol 
was completed with the application of 10 μM of norepi-
nephrine (NE) to assess the viability of the trabeculae.
Protocols
To determine the effects of modulation of the NO path-
way, the non-selective inhibitor of NOS – N-methyl-L-argi-
nine (LNMMA), the donor of NO – S-nitroso-N-acetylpen-
icillamine (SNAP) or morphine (in the amount of 10−4 M) 
were used at the time of re-oxygenation. The other trabec-
ula was subjected only to the hypoxia protocol (control). 
The experimental protocols are depicted in Fig. 1.
The  contractility of  the  myocardium assessed 
as the maximal force of a contraction (maximal ampli-
tude of the peak – Amax), the rate of rise of  the force 
of a contraction (the slope of the leading edge of the peak 
Table 1. The patients’ demographic data, preoperative drug treatment 
and preoperative left ventricular ejection fraction
1 men/women, n 35/23
2 age [years] 62.8 ±5.7
3 ejection fraction, mean ±SD 52.3 ±2.39%
4a diabetes, n (%) 12 (20)
4b diabetes with insulin treatment, n (%) 7 (12)
5 Drugs, n (%)
5a beta-blockers 43 (75)
5b calcium channel blockers 10 (18)
5c angiotensin II converting enzyme inhibitors 30 (52)
5d angiotensin II receptor blockers 2 (3)
5e statins 40 (69)
SD – standard deviation.
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– Slope L) and the cardiac muscle relaxation – as the rate 
of decay of the force of a contraction (the slope of trailing 
edge of the peak – Slope T) were obtained in the 5th, 10th, 
15th, 30th, 45th, and 60th min of re-oxygenation and after 
the NE application.
Data analysis
The results are presented as the percentages of the values 
obtained before the experimental protocol application. 
All continuous data is presented as a mean ± standard 
error of the mean (SEM). Two-way analysis of variance 
(ANOVA) with Holm-Sidack test was used to compare 
the values from the 5th to the 60th min of re-oxygenation. 
The p-values <0.05 were considered statistically signifi-
cant. Statistical analysis was performed using SigmaPlot 
software v. 10.0.1.2. (Systat Software Inc., San Jose, USA).
The approval of the local bioethics committee for the use 
of human tissue was obtained and individual patient con-
sent was waived. All experiments were performed accord-
ing to the principles stated in the Declaration of Helsinki.
Results
There were no significant differences in age, sex and 
pharmacotherapy between the  patients from whom 
the trabeculae were taken and subjected to each experi-
mental protocol.
The application of the NOS blocker – LNMMA at a con-
centration of 10−4 M resulted in the decrease of Amax, Slope 
L and Slope T as compared to control. The co-application 
of 10−4 M morphine with LNMMA, or the application 
of  LNMMA, morphine and SNAP at  a  concentration 
of 10−4 M partially reversed the detrimental effect of LNM-
MA. All detailed results are depicted in Fig. 2.
Discussion
Due to  the  role of  NO  in  cardioprotection, the  use 
of  NO  donors has been proposed for  the  prevention 
of I/R injury and the treatment of chronic cardiovascular 
diseases.
Accordingly to the earlier obtained data,we reported 
the cardioprotective effect of morphine on the function 
of the human heart muscle.6,7 In this study, we showed 
that  NO  plays an  important role in  intermediating 
the beneficial influence of opioids. The NOS blockade 
completely abrogated the  effect of  morphine. More-
over, the NOS blockade constituted a deleterious factor 
on the myocardium that  is strong enough to outweigh 
the protective influence of morphine and of the NO do-
nor. To  our knowledge, this is  the  first presentation 
of  the  fact that  the  NO  signaling pathway is  crucial 
in the mechanism of protection in relation to the func-
tion of the human heart muscle.
Previous studies on  the  inf luence of  opioids and 
the  NO  pathway on  I/R injury utilized mainly ani-
mal models. We assessed the effect of the co-operation 
of opioids with NO on the systolic and diastolic function 
of the hypoxic human myocardium in vitro. Our study 
was performed on isolated fragments of the human right 
















Fig. 2. The effect of N-methyl-l-arginine (LNMMA), morphine (Mp)  
and/or S-nitroso-N-acethylpenicillamine (SNAP) on the function 
of the human myocardium during the re-oxygenation period
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atria. For functional studies, due to atrial tissue sampling, 
it is possible to avoid the influence of confounding factors, 
like the effect of drugs or the presence of collateral circula-
tion. In this model we did not assess the infarct size, but 
the differences of contractility as functional consequences 
of cardiac ischemia.
Morphine is  commonly used as  an  analgetic drug 
in acute myocardial infarction. This was the first opioid 
drug shown to  be cardioprotective against I/R injury. 
Opioids also appear to mediate cardioprotective strate-
gies – IPC and POC, brief non-lethal episodes of acute 
lethal I/R injury – applied respectively before the onset 
of the re-oxygenation period.8,9 The beneficial effect of opi-
oids, IPC or POC has been shown in many studies using 
animal models and clinical trials,although the intracellular 
mechanism responsible for this phenomena remains not 
fully understood.10–12
It is well-known that NO acts as a modulator of the anal-
getic effect of morphine and the inhibitors of the NO/cGMP 
pathway attenuate this effect.13 Several studies reported 
that the NO inhalation effectively reduced the infarct size 
of  the heart muscle and improved the cardiac function 
in porcine and rodent models of I/R injury.14,15 Recently, 
it has been shown that remote intrathecal fentanyl precon-
ditioning induces cardioprotective effects in rats via the ac-
tivation of NOS, and that the NOS inhibitor – N omega- 
-nitro-L-arginine methyl ester (L-NAME) abolished this 
effect.16,17 Further studies highlight the role of the increased 
expression and activity of NOS in delayed protective ef-
fects of IPC.18 POC also increases NOS activity; likewise, 
the NOS blockade with L-NAME abrogates the beneficial 
effect of POC.19
In our study, the use of  the NO-donor, SNAP, im-
proved the  systolic and diastolic function of  human 
myocardium in the re-oxygenation period. In a rat mod-
el, the administration of SNAP reduced the size of ne-
crosis.20 Moreover, the use of a substrate for the synthe-
sis of NO, L-arginine, resulted in a reduction in infarct 
size and improved the cardiac systolic function.19 Apart 
from the fact that SNAP releases NO, providing a me-
diator of intracellular pathways, it has also the ability 
to inhibit the inducible NOS (iNOS) expression, respon-
sible for the synthesis of the highly reactive peroxyni-
trite (ONOO−), preventing damage generated by oxi-
dative stress.21 Although higher SNAP concentrations 
did not confer protection, which results from twofold 
nature of NO.20 The cardioprotective effect depends 
on the balance between NO and reactive oxygen spe-
cies (ROS). ROS released during re-oxygenation lead 
to the opening of mPTP, which triggers the depolariza-
tion of  the mitochondrial inner membrane, resulting 
in the adenosine triphosphate (ATP) depletion, the re-
spiratory chain inhibition and the rupture of  the mi-
tochondrial outer membrane. The activation of pro-
tein kinases, such as Akt, glycogen synthase kinase 3β 
(GSK-3β), which consists of  the element downstream 
of NO/cGMP in  the  intracellular pathway of opioids, 
prevents the opening of mPTP.22 Physiological NO con-
centration inhibits the mPTP opening, whereas a high 
concentration of NO favors the creation of ONOO− and 
triggers the  mPTP opening related to  the  formation 
of disulfide bonds.23 Furthermore, the transient activa-
tion of NOS during reperfusion involves the rapid con-
sumption of L-arginine and tetrahydrobiopterin, causing 
the production of the superoxide anion instead of NO.24
It  is  feasible that  the  cooperation of  opioids with 
NO in the cardioprotective effect arises from the com-
mon signaling pathway. On the contrary, the double-edge 
sword effect of NO donors explains the diverging results, 
which is reflected in the exogenous nitrate tolerance.24
Limitations
The results must be interpreted within the limitations 
of the methodology. The construction of our experiment 
assumes a control group derived from the same patient, 
and the  same factors potentially affecting the  test. 
We  must note, however, that  the  simulated ischemic 
model differs from in vivo conditions. In our experi-
ment, we utilized the buffer, so there were no elements 
transporting or  binding opioids, like peptides. How-
ever, the  pathophysiological and functional changes 
that took place in our model of I/R injury are compa-
rable to the change that takes place in in vivo conditions. 
The instantaneous NO concentration is crucial in many 
processes, but its evaluation is hard to obtain, which con-
stitutes the limitation of the method.
Conclusions
In the re-oxygenation period, the blockade of NO syn-
thesis has a deleterious effect on the systolic and diastolic 
function of the human myocardium.
All protocols were preceded by a stabilization period 
of 45–60 min. This was followed by 60 min of simulated 
ischemia (superfusion with the hypoxic, substrate-free 
Krebs-Henseleit solution and a pacing at 1 Hz) and 60 min 
of superfusion with the re-oxygenated Krebs-Henseleit 
solution. In protocols with a pharmacological modifica-
tion, N-methyl-L-arginine at a concentration of 10−4 M, 
S-nitroso-N-acetylpenicillamine at  a  concentration 
of 10−4 M and/or morphine at a concentration of 10−4 M 
were used. Control – the protocol with hypoxia condi-
tions only.
Figures present parameters of the contraction as max-
imal force of  a  contraction (Amax), the  rate of  rise 
of the force of a contraction (Slope L) and the relaxation 
parameter – the rate of decay of the force of a contraction 
(Slope T); * indicates significantly higher values (p < 0.05) 
vs LNMMA.
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